VIVACY Laboratories, a globally recognized leader in the design, production, and distribution of high-end medical devices for aesthetic and restorative medicine, recently hosted a landmark event at its headquarters to celebrate the official debut of Novuma. This new addition to the company’s portfolio represents a significant leap forward in the field of regenerative aesthetics, specifically utilizing calcium hydroxylapatite (CaHA) technology. The launch event served as a focal point for the aesthetic community, bringing together distinguished faculty members, clinical practitioners, and industry experts to witness the clinical application and strategic integration of this next-generation injectable.
The afternoon began with an intensive networking session, allowing delegates to discuss the evolving landscape of non-surgical facial rejuvenation. The guest list featured some of the most prominent names in the United Kingdom’s aesthetic sector, including Dr. Zunaid Alli, Dr. Cemal Kavasogullari, and Dr. Thuha Jabbar. These faculty members provided a professional framework for the event, offering insights into how Novuma fits into modern treatment algorithms that increasingly favor biostimulation and long-term tissue health over simple volumetric filling.
The Evolution of Regenerative Medicine at VIVACY Laboratories
The introduction of Novuma marks a pivotal moment in VIVACY’s history. For years, the laboratory has been synonymous with its STYLAGE range, a collection of hyaluronic acid (HA) fillers known for their patented IPN-Like technology and the inclusion of antioxidants like mannitol. However, as the global aesthetic market shifts toward "regenerative medicine"—a discipline focused on restoring the body’s natural functions and structures—VIVACY has expanded its research and development to include biostimulatory agents.
Novuma is engineered as a calcium hydroxylapatite (CaHA) injectable, a substance that has long been respected in the medical community for its biocompatibility and its ability to act as a scaffold for new collagen growth. Unlike traditional HA fillers, which primarily work by binding water to create volume, CaHA injectables like Novuma provide a dual-action result: an immediate mechanical lift provided by the gel carrier and a sustained improvement in skin quality through the stimulation of endogenous collagen and elastin.
Clinical Demonstration and Protocol Precision
A highlight of the launch event was a live clinical demonstration conducted by Dr. Zunaid Alli. As a highly regarded aesthetic practitioner and educator, Dr. Alli’s involvement provided delegates with a practical understanding of Novuma’s rheology and handling characteristics. During the demonstration, Dr. Alli outlined a specific treatment protocol, emphasizing the importance of injection depth and technique to maximize the regenerative potential of the product.
The demonstration focused on the mid-to-lower face, areas where structural support is often lost due to the aging process. Dr. Alli detailed the product volume used, explaining how Novuma’s specific formulation allows for precise placement and predictable outcomes. By showcasing the product in a live setting, VIVACY aimed to demystify the complexities of CaHA injections, which require a different level of anatomical knowledge and technical finesse compared to standard hyaluronic acid treatments.
Faculty members Dr. Cemal Kavasogullari and Dr. Thuha Jabbar also contributed to the discourse, discussing patient selection and the synergy between Novuma and other modalities, such as skin boosters or energy-based devices. The consensus among the faculty was that Novuma provides a "structural foundation" that enhances the overall longevity and natural appearance of aesthetic interventions.
Technical Specifications: The Science of Novuma
To understand the impact of Novuma, one must examine the science of calcium hydroxylapatite. CaHA is a mineral naturally found in human bones and teeth, which minimizes the risk of allergic reactions or biocompatibility issues. In Novuma, the CaHA microspheres are suspended in a carboxymethylcellulose (CMC) gel carrier.
Upon injection, the CMC gel provides immediate correction of folds and wrinkles. Over a period of several months, the body metabolizes the gel, while the CaHA microspheres remain at the injection site. These microspheres act as a biological trigger, stimulating fibroblasts to produce Type I collagen. This process, known as neocollagenesis, results in a firmer, more resilient dermal structure that lasts well beyond the lifespan of the initial gel carrier.
VIVACY’s entry into this specific niche is strategic. Data from global aesthetic market reports suggest that the demand for biostimulators is growing at a faster rate than traditional fillers. Patients are increasingly seeking "undetectable" work, moving away from the "over-filled" look and toward treatments that improve the intrinsic quality of their skin. Novuma is positioned to meet this demand by offering a solution that bridges the gap between traditional volumization and advanced tissue regeneration.
Strategic Leadership and Market Positioning
Katie Hughes-Dawkins, the Sales Director at VIVACY Laboratories, provided the corporate vision during the event. She noted that Novuma was developed to satisfy a dual requirement in the modern clinic: immediate aesthetic satisfaction and long-term structural improvement. Her comments highlighted VIVACY’s commitment to "premium" solutions, reinforcing the brand’s reputation for quality and innovation.
"As our next-generation CaHA technology, Novuma has been developed to meet immediate aesthetic improvement and long-term tissue regeneration," Hughes-Dawkins stated. She further emphasized that the product strengthens VIVACY’s portfolio, which now offers a comprehensive suite of tools for the "regenerative medicine" era.
The launch of Novuma is also a testament to VIVACY’s robust manufacturing capabilities. Based in Archamps, France, near the Swiss border, the company maintains total control over its production chain. This vertical integration ensures that every syringe of Novuma meets stringent European and international safety standards, a factor that is increasingly important to practitioners in a highly regulated and scrutinized industry.
Analyzing the Broader Impact on the Aesthetic Industry
The introduction of Novuma into the UK and European markets is likely to influence several key trends in the aesthetic sector:
- The Rise of Hybrid Protocols: Practitioners are expected to combine Novuma with VIVACY’s STYLAGE range to provide "layered" rejuvenation. While HA fillers provide hydration and soft volume, Novuma provides the structural "scaffolding" required for a lifted appearance.
- Increased Focus on Skin Quality: By promoting collagen and elastin production, Novuma addresses the "crepiness" and laxity of the skin, which traditional fillers cannot always resolve. This aligns with the "pre-juvenation" trend among younger demographics who wish to maintain their collagen levels before significant aging occurs.
- Economic Resilience of the Aesthetic Sector: Despite broader economic fluctuations, the premium aesthetic market remains robust. Products like Novuma, which offer long-lasting results (often 12 to 18 months), provide a high value-to-cost ratio for patients, making them a staple in high-end clinical settings.
- The Shift Toward Physician-Led Innovation: The involvement of faculty like Dr. Alli and Dr. Jabbar underscores a trend where manufacturers collaborate closely with clinical experts to ensure that products are not only safe but also optimized for the most advanced injection techniques.
Chronology of the Novuma Launch and Future Rollout
The headquarters event served as the official "ribbon-cutting" for Novuma, but the rollout is part of a broader, multi-phase strategy. Following the initial faculty-led demonstration, VIVACY plans to implement a series of regional training workshops across the United Kingdom and Europe. These workshops will focus on "The Novuma Technique," ensuring that a wider base of practitioners can safely and effectively integrate the product into their daily practice.
The timeline for Novuma’s integration into the global market is expected to follow a rigorous path of clinical education. By the end of the current fiscal year, VIVACY aims to have Novuma established as a primary choice for biostimulation in top-tier aesthetic clinics. The company’s focus on peer-to-peer education, as evidenced by the headquarters event, suggests that they view clinical excellence as the primary driver of commercial success.
Conclusion: A New Chapter in Aesthetic Excellence
The launch of Novuma by VIVACY Laboratories represents more than just the release of a new product; it signifies a maturing of the aesthetic industry. As the distinction between "filling" and "regenerating" becomes clearer, products like Novuma provide the scientific foundation for a more sophisticated approach to aging.
By hosting the event at their headquarters and involving a prestigious faculty, VIVACY has signaled its intention to remain at the forefront of the regenerative medicine movement. For practitioners, Novuma offers a versatile, evidence-based tool to address the complex needs of modern patients. For the industry at large, it marks the continued evolution of non-surgical procedures toward results that are not only visible but also biologically transformative.
As the aesthetic community continues to digest the data and clinical outcomes presented at the launch, Novuma is poised to become a cornerstone of VIVACY’s "premium" portfolio, further solidifying the laboratory’s role as a pioneer in the science of beauty and tissue longevity.
